Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era

Human Mutation

Volumn 35, Issue 6, 2014, Pages 766-778

  Soussi, Thierry ^a,b   Leroy, Bernard ^b   Taschner, Peter E M ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Annotation; Cancer; P53: mutation nomenclature; Recommendations; TP53

Indexed keywords

AMINO ACID; ISOPROTEIN; PROTEIN P53; TP53 PROTEIN, HUMAN;

CANCER INHIBITION; CANCER PROGNOSIS; CLINICAL EVALUATION; EXON; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; GERM LINE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; IMMUNOHISTOCHEMISTRY; INTRON; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; STANDARDIZATION; TREATMENT RESPONSE; GENETIC DATABASE; GENETICS; MUTATION; PATHOLOGY;

DATABASES, GENETIC; EXONS; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTRONS; MUTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901007659     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22561     Document Type: Review

References (70)

1. Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP, Bourdon JC. 2011. p53 directly transactivates Delta 133p53alpha, regulating cell fate outcome in response to DNA damage. Cell Death Differ 18:248-258.
2. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL, Overgaard J. 2008. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 47:600-607.
3. Auerbach AD, Burn J, Cassiman JJ, Claustres M, Cotton RG, Cutting G, den Dunnen JT, El-Ruby M, Vargas AF, Greenblatt MS, Macrae F, Matsubara Y, et al. 2011. Mutation (variation) databases and registries: a rationale for coordination of efforts. Nat Rev Genet 12:881; discussion 881.
4. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, et al. 2010. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715-721.
5. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP. 1991. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703.
6. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, et al. 2014. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24.
7. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-2137.
8. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ. 1996. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981.
9. Claustres M, Horaitis O, Vanevski M, Cotton RG. 2002. Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases. Genome Res 12:680-688.
10. Cotton RG, Auerbach AD, Axton M, Barash CI, Berkovic SF, Brookes AJ, Burn J, Cutting G, den Dunnen JT, Flicek P, Freimer N, Greenblatt MS, et al. 2008. GENETICS. The Human Variome Project. Science 322:861-862.
11. Cotton RG, Malcolm AD. 1991. Mutation detection. Nature 353:582-583.
12. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, et al. 2012. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486:346-352.
13. Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, Ledesma JA, Barbosa JR, et al. 2013. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol 31:2619-2626.
14. Dalgleish R, Flicek P, Cunningham F, Astashyn A, Tully RE, Proctor G, Chen Y, McLaren WM, Larsson P, Vaughan BW, Beroud C, Dobson G, et al. 2010. Locus Reference Genomic sequences: an improved basis for describing human DNA variants. Genome Med 2:24.
15. den Dunnen JT, Antonarakis SE. 2000. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7-12.
16. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. 2002. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9:12-16.
17. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, et al. 2010. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005.
18. Donehower LA. 2014. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Hum Mutat 35: 715-727.
19. Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundstrom M, Micke P, Botling J, Soussi T. 2012. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci USA 109:9551-9556.
20. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, Mu XJ, Khurana E, Rozowsky J, Alexander R, Min R, Alves P, et al. 2012. Architecture of the human regulatory network derived from ENCODE data. Nature 489:91-100.
21. Ghosh A, Stewart D, Matlashewski G. 2004. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24:7987-7997.
22. Gluck S, Ross JS, Royce M, McKenna EFJ, Perou CM, Avisar E, Wu L. 2012. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/- trastuzumab. Breast Cancer Res Treat 132:781-791.
23. Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, Guma S, Phan L, et al. 2012. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci USA 109:E1513-E1522.
24. Hall PA, Lane DP. 1994. p53 in tumour pathology: can we trust immunohistochemistry?-Revisited! J Pathol 172:1-4.
25. Hall PA, McCluggage WG. 2006. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 208:1-6.
26. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. 2006. The UMD TP53 database and website: update and revisions. Hum Mutat 27:14-20.
27. Jackson JG, Lozano G. 2013. The mutant p53 mouse as a pre-clinical model. Oncogene 32:4325-4330.
28. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. 2005. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 65:2108-2114.
29. Kamihara J, Rana HQ, Garber JE. 2014. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35:654-662.
30. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502:333-339.
31. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424-8429.
32. Kenzelmann Broz D, Attardi LD. 2010. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis 31:1311-1318.
33. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501.
34. Legros Y, Lafon C, Soussi T. 1994. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 9:2071-2076.
35. Leroy B, Anderson M, Soussi T. 2014a. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 35:672-688.
36. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. 2013. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 41:D962-D969.
37. Leroy B, Girard L, Minna JD, Gazdar AF, Soussi T. 2014b. Analysis of p53 mutation status in human cancer cell lines: a reassessment. Hum Mutat 35:756-765.
38. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. 2011. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol 12:259-265.
39. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, et al. 2013. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4529-4540.
40. MacArthur JA, Morales J, Tully RE, Astashyn A, Gil L, Bruford EA, Larsson P, Flicek P, Dalgleish R, Maglott DR, Cunningham F. 2014. Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants. Nucleic Acids Res 42:D873-D878.
41. Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman KG, Farnebo M. 2009. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 33:462-471.
42. Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. 2014. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Hum Mutat 35:663-671.
43. Marchetti A, Felicioni L, Buttitta F. 2006. Assessing EGFR mutations. N Engl J Med 354:526-528; author reply 526.
44. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716-7719.
45. Matlashewski G, Pim D, Banks L, Crawford L. 1987. Alternative splicing of human p53 transcripts. Oncogene Res 1:77-85.
46. Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC. 2007. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 16:214-222.
47. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, et al. 2013. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108-112.
48. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708.
49. Olivier M, Taniere P. 2011. Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Curr Opin Oncol 23:88-92.
50. Ortiz-Cuaran S, Cox D, Villar S, Friesen MD, Durand G, Chabrier A, Khuhaprema T, Sangrajrang S, Ognjanovic S, Groopman JD, Hainaut P, Le Calvez-Kelm F. 2013. Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma. Genes Chromosomes Cancer 52:912-919.
51. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. 2007. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357:2543-2551.
52. Phang BH, Chua HW, Li H, Linn YC, Sabapathy K. 2011. Characterization of novel and uncharacterized p53 SNPs in the Chinese population-intron 2 SNP co-segregates with the common codon 72 polymorphism. PLoS One 6:e15320.
53. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV. 2008. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282-1291.
54. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Dohner H, Hillmen P, van Oers M, et al. 2012. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26:1458-1461.
55. Reisman D, Balint é, Loging WT, Rotter V, Almon E. 1996. A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells. Genomics 38:364-370.
56. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, et al. 2001. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98:9330-9335.
57. Sah S, Chen L, Houghton J, Kemppainen J, Marko AC, Zeigler R, Latham GJ. 2013. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med 5:77.
58. Sauna ZE, Kimchi-Sarfaty C. 2011. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12:683-691.
59. Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C. 2006. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12:62-69.
60. Soussi T, Kato S, Levy PP, Ishioka C. 2005. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 25:6-17.
61. Soussi T, May P. 1996. Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol 260:623-637.
62. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, et al. 2011. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 43:1098-1103.
63. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. 1989. p53: a frequent target for genetic abnormalities in lung cancer. Science 246:491-494.
64. Taneja P, Zhu S, Maglic D, Fry EA, Kendig RD, Inoue K. 2011. Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol 5:235-257.
65. Tenaud C, Negoescu A, Labat-Moleur F, Legros Y, Soussi T, Brambilla E. 1994. p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Mod Pathol 7:853-859.
66. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137:413-431.
67. Wang B, Niu D, Lam TH, Xiao Z, Ren EC. 2013. Mapping the p53 transcriptome universe using p53 natural polymorphs. Cell Death Differ 21-521-532.
68. Wang GS, Cooper TA. 2007. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8:749-761.
69. Whibley C, Pharoah PD, Hollstein M. 2009. p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95-107.
70. Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, Sitbon G, Lundeberg J. 1999. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 155:1467-1471.